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. However, a fundamental question remains as to how the myriad of signals transduced by the ECs efficiently and differentially communicate to VSMCs, both during development and in response to haemodynamic stimuli in the adult.
Secreted growth factors are important regulators of the EC-VSMC interface. During embryonic angiogenesis, EC-mediated recruitment of pericytes to capillaries and VSMCs to arteries and veins is required for vessel maturation and stabilization. Platelet-derived growth factor B (PDGF-B) is secreted from the endothelium of angiogenic sprouts, where it serves as an attractant for co-migrating mural cells (a precursor to pericyctes and VSMCs) expressing the PDGFRβ receptor 2 . PDGF-B stimulates proliferation of VSMCs and induces mural cell fate in undifferentiated mesenchymal cells 2 . AngiopoietinTie receptor signalling occurs in the reverse direction, as the secretion of angiopoietin-1 by mural cells activates the Tie2 receptor on ECs, promoting pericyte adhesion and tightening of endothelial cell junctions 3 . Transforming growth factor-β ligands and their receptors stimulate mural cell induction, differentiation, proliferation and migration to the vessel wall 4 . 6 identify yet another means of EC-VSMC communication -secreted vesicles carrying miRNAs.
Conditional ablation of the
Blood vessels are constantly subjected to haemodynamic forces, including hydrostatic pressure, cyclic stretch and fluid shear stress, induced by pulsatile blood pressure and flow 7 . Shear stress, which is the component of frictional forces arising from blood flow acting parallel to the vessel luminal surface, is borne predominantly by ECs. Fluid shear stress modulates the structure and function of ECs by activating, or repressing, sets of genes, including many that have been implicated in the pathogenesis of atherosclerosis as well as other heritable and acquired vascular diseases. The exposure of ECs to shear stress or laminar flow induces the expression of a set of atheroprotective genes such as eNOS (endothelial nitric oxide synthase). Conversely, decreased shear stress at sites of disturbed laminar flow causes the downregulation of atheroprotective genes and the concomitant upregulation of a set of pro-atherogenic genes. One unanswered question concerns how physical forces influencing EC phenotype are transmitted to VSMCs, thus modulating their phenotype in segments of the vasculature predisposed to atherosclerosis and other vascular diseases.
Kruppel-like factor 2 (KLF2) is a lineagerestricted member of the Kruppel family of transcription factors that serves as a key 'molecular switch' , regulating important aspects of vascular function and disease 8 . KLF2 expression is rapidly induced in ECs exposed to fluid shear stress. Reduced KLF2 is observed in humans at sites of disturbed laminar flow, such as the bifurcation of the aorta, and branch points of the carotid, iliac and coronary arteries that are predisposed to atherosclerosis. KLF2 lies upstream in the transcriptional program, promoting the atheroprotective phenotype in ECs (ref. 7) . It induces expression of anti-inflammatory and anticoagulant proteins, and inhibits proinflammatory molecules including NF-κβ and its target genes. The combined effects of KLF2 and Nrf2, a KLF2-regulated transcription factor responsible for anti-oxidant gene expression, are thought to account for approximately 70% of shear-stress-induced changes in EC gene expression 9 . Klf2 -/-null mutant embryos survive only until embryonic days 12.5-14.5, succumbing to intra-embryonic and intra-amniotic haemorrhage attributable to a block in VSMC recruitment to the vessel wall, leading to aneurysm and arterial rupture 10 . EC-restricted knockout of the Klf2 gene leads to high-output heart failure caused by a marked decrease in peripheral resistance 11 . However, the mechanism by which KLF2 regulates arterial tone and vascular stability during embryonic development has been perplexing.
Hergenreider et al. now elucidate a previously unidentified pathway linking endothelial KLF2 expression to regulation of VSMC phenotype 6 . In 2009, three groups independently reported that miRNAs 143 and 145 influenced VSMC phenotype [12] [13] [14] . However, the source of miR-143 and miR-145, and regulation of the miR-143/145 complex, remained largely unexplored. Recent studies have revealed that both mRNAs and miRNAs can be secreted by cells and transported intercellularly by exosomes and other types of extracellular vesicles. For example, exosomes derived from glioblastoma cells were found to transport miRNAs to target cells and influence their phenotype 15 , and microvesicles from bone marrow and mesenchymal cells were found to transport bioactive miRNAs to target cells 16 . Recently, high-density lipoproteins from human plasma were found to contain a range of miRNAs with biological activity on target cells 17 . Thus, a paradigm is evolving in which cells can secrete certain miRNAs in extracellular vesicles that can be transported in interstitial fluid to nearby cells or can hijack plasma lipoproteins for plasmabased transport, with uptake by target cells and subsequent effects on their phenotype.
As illustrated in Fig. 1 , the report by Hergenreider et al. provides a compelling demonstration of intercellular communication between ECs and VSMCs mediated by extracellular vesicles bearing miRNAs 6 . Having previously demonstrated that miR-143 and miR-145 regulate VSMC phenotype 12 , the authors noted that shear stress upregulated expression of the two miRNAs in endothelial cells through a KLF2-dependent mechanism both in vitro and in vivo. KLF2-binding sites were identified in the promoter of miR-143/145, and the authors observed direct promoter activation by either KLF2 or shear stress in reporter assays. Hergenreider et al. went on to show that KLF2-expressing ECs secrete extracellular vesicles comparable in size to exosomes (as determined by electron microscopy) that are enriched in miR-143 and miR-145. Using an EC-VSMC co-culture system, they demonstrated transfer of these miRNAs from ECs to VSMCs and, strikingly, a clear effect of these miRNAs in reducing the mRNA abundance of known target genes in the VSMCs. VSMC gene expression and phenotype were altered in a manner predicted to be atheroprotective. This included suppression of KLF4 and Elk1, which suppress VSMC differentiation in response to oxidized phospholipids 18 . The authors proved this was not simply an in vitro phenomenon by isolating vesicles from the media of cultured KLF2-expressing ECs and repeatedly injecting them into atherosclerosis-prone mice, demonstrating a reduction in the disease. This result was dependent on expression of both KLF2 and miR-143/145 in the cultured ECs that served as the source of extracellular vesicles.
This exciting finding has important implications for vascular biology and the broader miRNA scientific community. For vascular biologists, it provides a plausible mechanistic link between laminar flow-induced endothelial KLF2 expression and atheroprotective VSMC phenotype, the nature of which has been uncertain. This means of EC-SMC communication and signaling also helps to provide molecular details that may in part underlie the well-established, but as yet poorly understood, association between endothelial shear stress and atherosclerosis. For the exploding field of miRNA biology, this report is one of the best demonstrations to date of intercellular transport of specific miRNAs via extracellular vesicles, with effects on target cells that go beyond the demonstration of changes in mRNA abundance to show unequivocal impact on cell phenotype and pathogenesis of disease. In light of these results, miRNAs must be considered, alongside proteins, lipids and metabolites, as intercellular biological mediators, providing a potential explanation for the currently unexplained ability of one cell type to communicate with and influence the phenotype of other cells.
Despite the elegant exposition of the pathway, however, many questions remain. How is the release of the vesicles by ECs regulated, and do they contain other mediators, miRNAs or other, that modulate the effects of miR-143/145 or directly influence VSMC phenotype? How are the miRNAs taken up by VSMCs so that they avoid intracellular degradation and remain biologically active? If VSMC expression of endogenous miR-143/145 is normally high except in the setting of injury, how does EC-derived miR-143/145 influence VSMC phenotype? How might these results be exploited in the development of a novel therapeutic approach to atherosclerosis? What other processes during embryonic development and postnatal adaptation of the vasculature are regulated through vesicle-mediated transport and targeting of miRNAs? Now that this pathway of intercellular communication has been firmly established, it will be fascinating to see where it leads. Good neighbours in the tumour stroma reduce oxidative stress
Ralph J. DeBerardinis
Tumour cells undergo oncogene-regulated metabolic reprogramming that maximizes survival and growth. However, little is known about metabolic interactions between tumour cells and their non-malignant neighbours in the stroma. Bone-marrow-derived stromal cells are now shown to provide cysteine, an essential nutrient that enables leukaemia cells to resist oxidative stress.
Cancer cells thrive under stressful conditions, out-competing their neighbours for nutrients and other resources needed for survival and growth. This requires reprogramming of their metabolism to promote rapid energy generation, macromolecular synthesis and redox homeostasis, culminating in improved cellular fitness. There is now intense interest in identifying tumour-specific metabolic activities and in learning which activities are necessary for tumour-cell survival, as such pathways would be appealing therapeutic targets 1, 2 . Historically, the vast majority of cancer metabolism research has focused on cell-autonomous activities, particularly those related to bioenergetics and biosynthesis. This approach reaches back to Otto Warburg's studies on tumour glycolysis in the 1920s, and has been reinforced recently by a large amount of work on the control of metabolism by oncogenes and tumour suppressors 3 . By contrast, metabolic interactions between tumour cells and supporting stromal tissue are poorly characterized. Given the well-known functions of stromal cells in facilitating other aspects of tumorigenesis 4 , it seems highly plausible that they also help coordinate the metabolic tasks needed for tumour-cell stress resistance. On page 276 of this issue, Zhang et al. 5 report that stromal cells support the survival of chronic lymphocytic leukaemia (CLL) cells by providing them with cysteine, a nutrient essential for resistance to oxidative stress and chemotherapeutic agents.
CLL is the most common adult leukaemia in Western countries 6 . The disease is remarkable in that most patients are diagnosed during a prolonged asymptomatic phase, which may last for decades. During this period, patients maintain a burden of viable malignant cells in their hematopoietic and lymphoid organs. However, exposure of these seemingly durable cells to standard tissue culture conditions causes glutathione depletion within 24 h, increased sensitivity to oxidative stress and rapid cell death 7 . Zhang et al. investigated whether mimicking in vivo conditions by co-culturing primary CLL cells with bone-marrow-derived stromal cells (BMSCs) could reverse this fatal phenomenon. They determined that several independent BMSC cell lines could protect CLL cells against reactive oxygen species (ROS), in part by bolstering glutathione levels. Under these conditions, the CLL cells also displayed increased resistance to F-ara-A and oxaliplatin, two chemotherapeutic agents used clinically to treat CLL.
Further experiments demonstrated that a low-molecular-weight compound secreted by BMSCs into the medium was responsible for the enhanced CLL cell survival. The authors identified the secreted factor as cysteine, one of the three amino acids required to synthesize glutathione. Most cells, including cancer cells, do not rely on extracellular cysteine for glutathione biosynthesis. Rather, they take up the more abundant and more stable oxidized form, cystine (two cysteine molecules joined by a disulfide bond), and reduce it to cysteine inside the cell. Cystine is taken up using the Xcantiporter, a multimeric amino-acid transporter that exchanges glutamate for cystine at the cell surface ( Fig. 1) . In the present study, Zhang et al. showed that whereas BMSCs expressed high levels of this transporter, CLL cells did not, and although they could avidly take up a radioactive cysteine tracer, they imported only minimal amounts of cystine. The authors also demonstrated that to maintain their glutathione stores and to counteract oxidative stress, CLL cells required either that the cell culture medium be supplemented with cysteine, or that the cells be co-cultured with BMSCs in cystine-replete medium. Furthermore, blocking BMSC Xc-function with a chemical inhibitor suppressed CLL cell viability and improved the efficacy of chemotherapeutic agents, both in an in vitro co-culture model and in a mouse model of CLL. Together, the data demonstrate that to counteract oxidative stress and death, CLL cells capitalize on the ability of their stromal cell neighbours to take up cystine and release cysteine.
Zhang et al. describe a previously unsuspected level of metabolic cooperativity between tumour cells and their non-transformed counterparts in the stroma. Importantly, analogous mechanisms of obligate metabolite exchange between supportive and parenchymal cells are a common theme in metazoans, and seem to be essential for the function of numerous tissues. Classical studies revealed that the earliest stages of mammalian development require that oxidizable substrates like pyruvate be transferred from follicular cells into the oocyte, before and shortly after fertilization 8 . In the brain, an astrocyte-to-neuron lactate shuttle is suspected to contribute to neuronal bioenergetics. In this model, glycolytic astrocytes release lactate into
